INSM P/E Ratio | INSMED INC

INSMED Inc PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

INSMED Inc pe ratio for the quarter ending 2026-06-30 was -26.6, a change of -6.06 year-over-year.
INSMED Inc pe ratio for the quarter ending 2026-03-31 was -29.91, a change of -16.21 year-over-year.
INSMED Inc pe ratio for the quarter ending 2025-12-31 was -29.21, a change of -15.66 year-over-year.
INSMED Inc pe ratio for the quarter ending 2025-09-30 was -25.85, a change of -10.75 year-over-year.
INSMED Inc pe ratio for fiscal 2026 was -26.6.
INSMED Inc pe ratio for fiscal 2025 was -29.21, a change of -15.66 from fiscal 2024.
INSMED Inc pe ratio for fiscal 2024 was -13.55, a change of -7.44 from fiscal 2023.
INSMED Inc pe ratio for fiscal 2023 was -6.12, a change of -0.49 from fiscal 2022.

Available history: 2011-03-31 to 2026-06-30
Data captured: 2026-06-30

Historical PE Ratio

Date	PE Ratio	Market capitalization	Net income 12 month
2026-06-30	-26.6	$23.28B	-$875.31M
2026-03-31	-29.91	$35.41B	-$1.18B
2025-12-31	-29.21	$37.29B	-$1.28B
2025-09-30	-25.85	$30.61B	-$1.18B
2025-06-30	-20.54	$21.25B	-$1.03B
2025-03-31	-13.7	$13.88B	-$1.01B
2024-12-31	-13.55	$12.38B	-$913.77M
2024-09-30	-15.11	$13.06B	-$864.29M
2024-06-30	-13.91	$11.17B	-$802.69M
2024-03-31	-5.4	$4.03B	-$746.89M
2023-12-31	-6.12	$4.59B	-$749.57M
2023-09-30	-4.99	$3.61B	-$723.63M
2023-06-30	-4.33	$3.01B	-$695.84M
2023-03-31	-4.26	$2.33B	-$546.68M
2022-12-31	-5.63	$2.71B	-$481.53M
2022-09-30	-6.04	$2.62B	-$434.39M
2022-06-30	-5.68	$2.36B	-$415.96M
2022-03-31	-6.41	$2.8B	-$437.63M
2021-12-31	-7.44	$3.23B	-$434.65M
2021-09-30	-7.69	$3.26B	-$423.89M
2021-06-30	-8.75	$3.28B	-$374.83M
2021-03-31	-11.01	$3.52B	-$319.37M
2020-12-31	-11.63	$3.42B	-$294.09M
2020-09-30	-13.36	$3.27B	-$244.87M
2020-06-30	-11.55	$2.79B	-$241.89M
2020-03-31	-5.84	$1.44B	-$246.55M
2019-12-31	-8.42	$2.14B	-$254.34M
2019-09-30	-5.38	$1.58B	-$292.92M
2019-06-30	-7.14	$2.28B	-$319.98M
2019-03-31	-6.84	$2.26B	-$329.91M
2018-12-31	-3.13	$1.01B	-$324.28M
2018-09-30	-5.23	$1.56B	-$298.09M
2018-06-30	-7.13	$1.82B	-$255.52M
2018-03-31	-7.71	$1.73B	-$223.76M
2017-12-31	-12.4	$2.39B	-$192.65M
2017-09-30	-12.21	$2.39B	-$195.67M
2017-06-30	-5.69	$1.07B	-$188.25M
2017-03-31	-6.03	$1.09B	-$180.16M
2016-12-31	-4.65	$820.52M	-$176.27M
2016-09-30	-6.46	$898.47M	-$139.12M
2016-06-30	-4.61	$610.12M	-$132.32M
2016-03-31	-6.3	$783.93M	-$124.35M
2015-12-31	-9.49	$1.12B	-$118.18M
2015-09-30	-10.97	$1.15B	-$104.59M
2015-06-30	-15.45	$1.51B	-$97.61M
2015-03-31	-11.28	$1.04B	-$92.23M
2014-12-31	-9.73	$770.5M	-$79.16M
2012-12-31	-5.09	$210.66M	-$41.37M
2012-09-30	-4.16	$141.86M	-$34.09M
2012-06-30	-1.37	$81.09M	-$59.29M
2012-03-31	-1.51	$90.3M	-$59.62M
2011-12-31	-1.27	$75.74M	-$59.66M
2011-09-30	-2.2	$126.15M	-$57.35M
2011-06-30	-12.9	$297.69M	-$23.09M
2011-03-31	-12.46	$167.59M	-$13.45M

Annual PE Ratio

Date	PE Ratio	Market capitalization	Net income 12 month
2026-06-30	-26.6	$23.28B	-$875.31M
2025-12-31	-29.21	$37.29B	-$1.28B
2024-12-31	-13.55	$12.38B	-$913.77M
2023-12-31	-6.12	$4.59B	-$749.57M
2022-12-31	-5.63	$2.71B	-$481.53M
2021-12-31	-7.44	$3.23B	-$434.65M
2020-12-31	-11.63	$3.42B	-$294.09M
2019-12-31	-8.42	$2.14B	-$254.34M
2018-12-31	-3.13	$1.01B	-$324.28M
2017-12-31	-12.4	$2.39B	-$192.65M
2016-12-31	-4.65	$820.52M	-$176.27M
2015-12-31	-9.49	$1.12B	-$118.18M
2014-12-31	-9.73	$770.5M	-$79.16M
2012-12-31	-5.09	$210.66M	-$41.37M
2011-12-31	-1.27	$75.74M	-$59.66M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64
Viatris Inc (VTRS)	United States	$20.008B	-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Jazz Pharmaceuticals plc (JAZZ)		$15.333B	16.07
Summit Therapeutics Inc. (SMMT)	United States	$13.071B	-13.21
BridgeBio Pharma, Inc. (BBIO)	United States	$12.947B	-20.72
CORCEPT THERAPEUTICS INC (CORT)	United States	$12.804B	169.10